In this podcast, Motley Fool senior analyst Jason Moser discusses: Highlights from Johnson & Johnson's (NYSE: JNJ) medical device and consumer health divisions. The spinoff of the consumer health division coming in late 2023. Read More...
Benzinga
Jim Cramer’s REIT Picks From April Reveal Alarming Truth
Jim Cramer is a lightning rod when it comes to scrutiny. On one hand, giving investing advice every day on air for years is naturally going to produce some losing picks. However, Cramer has become the focal point of a lot of targeted opposition. For instance, you can check out his ongoing (albeit one-sided) feud with George Noble, who is quick to call out Cramer. Or, you could check out the Journal of Retirement’s in-depth study of Cramer’s Charitable Trust performance and see that “Cramer’s por
